K
Kyverna Therapeutics, Inc. (KYTX)
NMS – Real Time Price. Currency in USD
8.44
+0.24 (2.93%)
At close: Jun 26, 2026, 4:00 PM EDT
8.44
0.00 (0.00%)
After-hours: Jun 26, 2026, 6:02 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
8.44
+0.24 (2.93%)
At close: Jun 26, 2026, 4:00 PM EDT
8.44
0.00 (0.00%)
After-hours: Jun 26, 2026, 6:02 PM EDT
No Data
There are no news for this stock.
Cash reserves $32.2M barely cover the upcoming debt maturities $33.8M
Total current assets $241.7M exceed Total current liabilities $29.7M, highlighting excellent liquidity
Debt-to-equity ratio (0.2) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-62.0x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$41.6M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 8.15 | 6.05 | 10 | |
| Quick ratio | 8.15 | 5.63 | 10 | |
| Debt to Equity | 0.17 | 0.30 | 9.0 | |
| Debt to Assets | 0.13 | 1.04 | 8.0 | |
| Interest coverage | -62.02 | -16.91 | 1.0 | |
| Weighted average score | 7.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 7M | N/A | N/A | N/A | N/A |
| Gross Profit | 6M | -2M | -2M | -2M | -2M |
| Operating Income | -29M | -62M | -143M | -169M | -164M |
| Net Income | -29M | -60M | -127M | -161M | -156M |
| EBITDA | -28M | -61M | -140M | -167M | -162M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 30.05 | 5.5 |
| Next quarter | N/A | 13.78 | 4.5 |
| Current year | N/A | 21.28 | 5.5 |
| Next year | N/A | -2.66 | 1.0 |
| Weighted average score | 4.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -5.08 | 17.5 | -22.1 | 5.3 |
| Y/Y | 999 | 10.99 | 35.92 | 7.39 | 8.0 |
| 3y average | 632.67 | -82.19 | 43.49 | -65.43 | 5.5 |
| 5y average | N/A | N/A | N/A | N/A | 1.0 |
| Weighted average score | 5.0 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |